Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 01, 2015 5:23 PM ET

Biotechnology

Company Overview of Zafgen, Inc.

Company Overview

Zafgen, Inc., a biopharmaceutical company, focuses on the development of therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection, which is in Phase III clinical trials for the treatment of obesity and hyperphagia in Prader-Willi Syndrome patients; that has completed Phase II clinical trials for the treatment of hypothalamic injury-associated obesity, including craniopharyngioma-associated obesity; and which is in Phase IIb clinical trials for the treatment of severe obesity in the general population. The company is also developing ZGN-839, a methionine aminopeptidase 2 inhibitor, which is in preclinical studi...

175 Portland Street

4th Floor

Boston, MA 02114

United States

Founded in 2005

38 Employees

Phone:

617-622-4003

Key Executives for Zafgen, Inc.

Chief Executive Officer and Director
Age: 55
Total Annual Compensation: $425.0K
President
Age: 52
Total Annual Compensation: $195.4K
Chief Financial Officer
Age: 53
Total Annual Compensation: $297.9K
Chief Medical Officer
Age: 45
Total Annual Compensation: $407.0K
Chief Commercial Officer
Age: 52
Total Annual Compensation: $328.8K
Compensation as of Fiscal Year 2014.

Zafgen, Inc. Key Developments

Zafgen Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Zafgen reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported loss from operations of $17.6 million against $5.986 million a year ago. Net loss attributable to common stockholders was $17.756 million or $0.66 per diluted share against $6.443 million or $2.96 per diluted share a year ago. For the six months, the company reported loss from operations of $30.9 million against $10.5 million a year ago. Net loss attributable to common stockholders was $31.2 million or $1.19 per diluted share against $10.950 million or $7.51 per diluted share a year ago.

Zafgen, Inc., Q2 2015 Earnings Call, Aug 11, 2015

Zafgen, Inc., Q2 2015 Earnings Call, Aug 11, 2015

Zafgen, Inc. Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-12-2015 08:30 AM

Zafgen, Inc. Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-12-2015 08:30 AM. Venue: InterContinental Boston, 510 Atlantic Avenue, Boston, MA 02210, United States. Speakers: Thomas E. Hughes, Chief Executive Officer and Director.

Similar Private Companies By Industry

Company Name Region
Durata Therapeutics, Inc. United States
Genetronics Inc. United States
Midland Bioproducts Corporation United States
AVM Biotechnology LLC United States
Descartes Therapeutics United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Zafgen, Inc., please visit www.zafgen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.